Current and emerging immunomodulators for treatment of SARS-CoV2 infection (COVID-19)

References

• Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733.
   PubMed Web of Science ®Google Scholar
• Ward SE, Loutfy MR, Blatt LM, et al. Dynamic changes in clinical features and cytokine/chemokine responses in SARS patients treated with interferon alfacon-1 plus corticosteroids. Antivir Ther. 2005;10(2):263–275.
   PubMed Web of Science ®Google Scholar
• Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693–704. **The most important paper about immunomodulators published thus far.
   PubMed Web of Science ®Google Scholar
• Haider T, Gour V, Pandey V, et al. COVID-19 infection: targeting possibilities for treatment. Crit Rev Ther Drug Carrier Syst. 2021;38(3):75–115.
   PubMed Web of Science ®Google Scholar
• Pessoa-Amorim G, Campbell M, Fletcher L, et al. Making trials part of good clinical care: lessons from the RECOVERY trial. Future Healthc J. 2021;8(2):e243–e50.
   PubMedGoogle Scholar
• Fernandes M, Brábek J. COVID-19, corticosteroids and public health: a reappraisal. Public Health. 2021;197:48–55.
   PubMed Web of Science ®Google Scholar
• Buchman TG, Draghia-Akli R, Adam SJ, et al. Accelerating coronavirus disease 2019 therapeutic interventions and vaccines-selecting compounds for clinical evaluation in coronavirus disease 2019 clinical trials. Crit Care Med. 2021;49(11):1963–1973. *An excellent overview of the approach to randomized clinical trials.
   PubMed Web of Science ®Google Scholar
• Grobler JA, Anderson AS, Fernandes P, et al. Accelerated preclinical paths to support rapid development of COVID-19 therapeutics. Cell Host Microbe. 2020;28(5):638–645.
   PubMed Web of Science ®Google Scholar
• Hewitt JA, Lutz C, Florence WC, et al. ACTIVating resources for the COVID-19 pandemic: in Vivo models for vaccines and therapeutics. Cell Host Microbe. 2020;28(5):646–659.
   PubMed Web of Science ®Google Scholar
• Holz M, Mayerl J, Goli S. Early days of the pandemic-The association of economic and socio-political country characteristics with the development of the COVID-19 death toll. PLoS One. 2021;16(8):e0256736.
   PubMed Web of Science ®Google Scholar
• Moghadas SM, Galvani AP. The unrecognized death toll of COVID-19 in the United States. Lancet Reg Health Am. 2021;1:100033.
   PubMedGoogle Scholar
• Ouldali N, Toubiana J, Antona D, et al. Association of intravenous immunoglobulins plus methylprednisolone vs immunoglobulins alone with course of fever in multisystem inflammatory syndrome in children. JAMA. 2021;325(9):855–864.
   PubMed Web of Science ®Google Scholar
• Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed antiviral drugs for Covid-19 - Interim WHO solidarity trial results. N Engl J Med. 2021;384(6):497–511.
   PubMed Web of Science ®Google Scholar
• Bsteh G, Dürauer S, and Assar H, et al. Humoral immune response after COVID-19 in multiple sclerosis: a nation-wide Austrian study. Mult Scler. 2021;11:13524585211049391.
   Google Scholar
• Clark NM, Janaka SK, and Hartman W, et al. Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not facilitate antibody-dependent enhance of viral infection. bioRxiv. 2021;37:2911–2925.
   Google Scholar
• Desimmie BA, Raru YY, and Awadh HM, et al. Insights into SARS-CoV-2 persistence and its relevance. Viruses. 2021;13(6):1141–1152.
   PubMed Web of Science ®Google Scholar
• Ding C, He J, Zhang X, et al. Crucial mutations of spike protein on SARS-CoV-2 evolved to variant strains escaping neutralization of convalescent plasmas and RBD-Specific monoclonal antibodies. Front Immunol. 2021;12:693775.
   PubMed Web of Science ®Google Scholar
• Khaedir Y, Kartika R. Perspectives on targeting IL-6 as a Potential Therapeutic Strategy for COVID-19. J Interferon Cytokine Res. 2021;41(2):37–43.
   PubMed Web of Science ®Google Scholar
• Doyle EB, Bentley D, and Dodds MG. COVID-19 acute respiratory distress syndrome: a simulation study of the effects of combination therapy with tocilizumab and siltuximab. Br J Clin Pharmacol. 2021;38:3143–3158.
   Google Scholar
• Gritti G, Raimondi F, Bottazzi B, et al. Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19. Leukemia. 2021;35(9):2710–2714.
   PubMed Web of Science ®Google Scholar
• Meira F, Albiach L, Carbonell C, et al. Experience with the use of siltuximab in patients with SARS-CoV-2 infection. Rev Esp Quimioter. 2021;34(4):337–341.
   PubMed Web of Science ®Google Scholar
• Udwadia Z, Malu KN, R Tripathi AK. The case against tocilizumab. J Assoc Physicians India. 2021;69(4):11–12.
   PubMedGoogle Scholar
• Chen YW, Liao HT. Tocilizumab alleviates cytokine storm with acute respiratory distress syndrome in severe SARS-CoV-2 infection in Taiwan. Intern Med J. 2021;51(9):1543–1544. *An important overview of cytokine storm.
   PubMed Web of Science ®Google Scholar
• Amin S, Rahim F, Bahadur S, et al. The effect of tocilizumab on inflammatory markers in survivors and non-survivors of severe COVID-19. J Coll Physicians Surg Pak. 2021;31(1):S7–S10.
   PubMed Web of Science ®Google Scholar
• Tsai A, Diawara O, Nahass RG, et al. Impact of tocilizumab administration on mortality in severe COVID-19. Sci Rep. 2020;10(1):19131.
   PubMed Web of Science ®Google Scholar
• Morales-Avalos A, Vargas-Ponce KG, Idrogo-Alfaro JJ, et al. Experience of using tocilizumab in patients with COVID-19 from a referral hospital in Peru. Rev Peru Med Exp Salud Publica. 2021;38(2):360–362.
   PubMedGoogle Scholar
• Emadi A, Chua JV, Talwani R, et al. Safety and efficacy of imatinib for hospitalized adults with COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):897.
   PubMedGoogle Scholar
• Group RC. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637–1645.
   PubMed Web of Science ®Google Scholar
• Brown MJ, Alazawi W, Kanoni S. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. N Engl J Med. 2021;385(12):1147.
   PubMed Web of Science ®Google Scholar
• Mahroum N, Watad A, and Bridgewood C, et al. Systematic review and meta-analysis of tocilizumab therapy versus standard of care in over 15,000 COVID-19 pneumonia patients during the first eight months of the pandemic. Int J Environ Res Public Health. 2021;18(17):1027–1040.
   PubMed Web of Science ®Google Scholar
• Mouffak S, Shubbar Q, Saleh E, et al. Recent advances in management of COVID-19: a review. Biomed Pharmacother. 2021;143:112107.
   PubMed Web of Science ®Google Scholar
• Cheng Q, Chen J, and Jia Q, et al. Efficacy and safety of current medications for treating severe and non-severe COVID-19 patients: an updated network meta-analysis of randomized placebo-controlled trials. Aging (Albany NY). 2021;13(undefined):899–911.
   Google Scholar
• García-García JA, Pérez-Quintana M, and Ramos-Giráldez C, et al. Anakinra versus baricitinib: different strategies for patients hospitalized with COVID-19. J Clin Med. 2021;10(17):706–721.
   PubMed Web of Science ®Google Scholar
• Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384(9):795–807. **An excellent paper on the therapeutic potential of baricitinib in patietnts with COVID19. **An excellent paper on the therapeutic potential of baricitinib in patietnts with COVID19.
   PubMed Web of Science ®Google Scholar
• Guimarães PO, Quirk D, Furtado RH, et al. Tofacitinib in patients hospitalized with Covid-19 Pneumonia. N Engl J Med. 2021;385(5):406–415.
   PubMed Web of Science ®Google Scholar
• Mornese Pinna S, Lupia T, Scabini S, et al. Monoclonal antibodies for the treatment of COVID-19 patients: an umbrella to overcome the storm? Int Immunopharmacol. 2021;101(Pt A):108200.
   PubMedGoogle Scholar
• Claassen V, Davies JE, Hertting G, et al. Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor. Br J Pharmacol. 1977;60(4):505–516.
   PubMed Web of Science ®Google Scholar
• Saletu B, Schjerve M, Grünberger J, et al. Fluvoxamine-a new serotonin re-uptake inhibitor: first clinical and psychometric experiences in depressed patients. J Neural Transm. 1977;41(1):17–36.
   PubMed Web of Science ®Google Scholar
• Sukhatme VP, Reiersen AM, Vayttaden SJ, et al. Fluvoxamine: a review of its mechanism of action and its role in COVID-19. Front Pharmacol. 2021;12:652688.
   PubMed Web of Science ®Google Scholar
• Almási N, Török S, and Valkusz Z, et al. Sigma-1 receptor engages an anti-inflammatory and antioxidant feedback loop mediated by peroxiredoxin in experimental colitis. Antioxidants (Basel). 2020;9(11):2111–2121.
   Google Scholar
• Faraj BA, Olkowski ZL, Jackson RT. Expression of a high-affinity serotonin transporter in human lymphocytes. Int J Immunopharmacol. 1994;16(7):561–567.
   PubMed Web of Science ®Google Scholar
• Zedan M, Attia G, Zedan MM, et al. Clinical asthma phenotypes and therapeutic responses. ISRN Pediatr. 2013;2013:824781.
   PubMedGoogle Scholar
• Valera FC, Umezawa K, Brassesco MS, et al. Suppression of inflammatory cytokine secretion by an NF-ĸB inhibitor DHMEQ in nasal polyps fibroblasts. Cell Physiol Biochem. 2012;30(1):13–22.
   PubMedGoogle Scholar
• Rafiee L, Hajhashemi V, Javanmard SH. Fluvoxamine inhibits some inflammatory genes expression in LPS/stimulated human endothelial cells, U937 macrophages, and carrageenan-induced paw edema in rat. Iran J Basic Med Sci. 2016;19(9):977–984.
   PubMed Web of Science ®Google Scholar
• Williamson PA, Short PM, Vaidyanathan S, et al. Inhaled and systemic corticosteroid response in severe asthma assessed by alveolar nitric oxide: a randomized crossover pilot study of add-on therapy. Br J Clin Pharmacol. 2013;75(1):93–102.
   PubMed Web of Science ®Google Scholar
• Lenze EJ, Mattar C, Zorumski CF, et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA. 2020;324(22):2292–2300.
   PubMed Web of Science ®Google Scholar
• Seftel D, Boulware DR. Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19. Open Forum Infect Dis. 2021;8(2):ofab050.
   PubMed Web of Science ®Google Scholar
• Reis G, Dos Santos Moreira-Silva EA, and Silva DCM, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2021;81:4331–4339.
   Google Scholar
• Singh CV, Jain S, Parveen S. The outcome of fluticasone nasal spray on anosmia and triamcinolone oral paste in dysgeusia in COVID-19 patients. Am J Otolaryngol. 2021;42(3):102892.
   PubMed Web of Science ®Google Scholar
• Zilla ML, Keetch C, Mitchell G, et al. SARS-CoV-2 serologic immune response in exogenously immunosuppressed patients. J Appl Lab Med. 2021;6(2):486–490.
   PubMedGoogle Scholar
• Singh CV, Jain S, Parveen S, et al. The outcome of fluticasone nasal spray on anosmia and triamcinolone oral paste in taste dysgeusia in COVID-19 patients. Am J Otolaryngol. 2021;42(4):103009.
   PubMed Web of Science ®Google Scholar
• Caldwell JM, Blanchard C, Collins MH, et al. Glucocorticoid-regulated genes in eosinophilic esophagitis: a role for FKBP51. J Allergy Clin Immunol. 2010;125(4):879–88.e8.
   PubMed Web of Science ®Google Scholar
• Brown M, Phillips CB, Ciszek K, et al. Children in the ACT with asthma–are they taking preventer medication according to guidelines? Aust Fam Physician. 2010;39(3):146–149.
   PubMedGoogle Scholar
• Lechien JR, Hoch CC, Vaira LA, et al. The interest of fluticasone nasal spray in COVID-19 related anosmia is still not demonstrated. Am J Otolaryngol. 2021;42(4):103008.
   PubMed Web of Science ®Google Scholar
• Yavuz S, and Komsuoğlu ÇFI. Antiviral treatment of COVID-19: an update. Turk J Med Sci. 2021;19:2004–2015 .
   Google Scholar
• Cardwell K, O Murchu E, and Byrne P, et al. Pharmacological interventions to prevent Covid-19 disease: a rapid review. Rev Med Virol. 2021;39:e2299.
   Google Scholar
• Angelino G, Cifaldi C, and Zangari P, et al. Gastric cancer, inflammatory bowel disease and polyautoimmunity in a 17-year-old boy: CTLA-4 deficiency successfully treated with abatacept. Eur J Gastroenterol Hepatol. 2021;22:806–821.
   Google Scholar
• Grant RA, Morales-Nebreda L, Markov NS, et al. Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia. Nature. 2021;590(7847):635–641.
   PubMed Web of Science ®Google Scholar
• Argüelles-Arias F, Fernández Álvarez P, and Castro Laria L, et al. Switch to infliximab subcutaneous during SARS-CoV-2 pandemic: preliminary results. Rev Esp Enferm Dig. 2021;31:1765–1779.
   Google Scholar
• Attiq A, Yao LJ, Afzal S, et al. The triumvirate of NF-κB, inflammation and cytokine storm in COVID-19. Int Immunopharmacol. 2021;101(Pt B):108255.
   PubMedGoogle Scholar